Live feed08:00:00·4hPRReleasevia QuantisnowPraxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function VariantsByQuantisnow·Wall Street's wire, on your screen.PRAX· Praxis Precision Medicines Inc.Health Care
